Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.
Lymphoma, Non-Hodgkin
DRUG: immunochemotherapies
ORR, the ratio of numbers of patients with complete response and partial response to all the participants receiving treatment, up to 6 months
2-year progression-free survival (PFS), the period from the date of patients sign informed consent to the observed progression of the disease or the occurrence of death for any reason, From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|2-year event-free survival (EFS), the period from the date of patients sign informed consent to the observed event for any reason, From date of patients sign informed consent until the date of first documented event, progression or date of death from any cause, whichever came first, assessed up to 2 years|overall survival, time between the date of patients sign informed consent and the date of death or the date of last follow-up time, From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years|Hematology and non hematology toxicity, number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Throughout the treatment periodï¼Œup to 6 months
Evaluated the efficacy and safety of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL)